JP7767322B2 - 抗ａｂｃｇ２抗体及びそれらの使用 - Google Patents

抗ａｂｃｇ２抗体及びそれらの使用

Info

Publication number
JP7767322B2
JP7767322B2 JP2022574199A JP2022574199A JP7767322B2 JP 7767322 B2 JP7767322 B2 JP 7767322B2 JP 2022574199 A JP2022574199 A JP 2022574199A JP 2022574199 A JP2022574199 A JP 2022574199A JP 7767322 B2 JP7767322 B2 JP 7767322B2
Authority
JP
Japan
Prior art keywords
chain
antibody
abcg2
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022574199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528416A (ja
JP2023528416A5 (https=
JPWO2021247426A5 (https=
Inventor
ウィリアム ロバート アラスーン、
ラファエラ ブリアンテ、
スチスミタ モハンティ、
ポール デビッド ポナス、
リチャード テオリス、
キャンティン ツァイ、
ピンピン ツァン、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016
Original Assignee
ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 filed Critical ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016
Publication of JP2023528416A publication Critical patent/JP2023528416A/ja
Publication of JP2023528416A5 publication Critical patent/JP2023528416A5/ja
Publication of JPWO2021247426A5 publication Critical patent/JPWO2021247426A5/ja
Priority to JP2025182305A priority Critical patent/JP2026053316A/ja
Application granted granted Critical
Publication of JP7767322B2 publication Critical patent/JP7767322B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022574199A 2020-06-04 2021-05-28 抗ａｂｃｇ２抗体及びそれらの使用 Active JP7767322B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182305A JP2026053316A (ja) 2020-06-04 2025-10-29 抗ａｂｃｇ２抗体及びそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034806P 2020-06-04 2020-06-04
US63/034,806 2020-06-04
PCT/US2021/034947 WO2021247426A1 (en) 2020-06-04 2021-05-28 Anti-abcg2 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182305A Division JP2026053316A (ja) 2020-06-04 2025-10-29 抗ａｂｃｇ２抗体及びそれらの使用

Publications (4)

Publication Number Publication Date
JP2023528416A JP2023528416A (ja) 2023-07-04
JP2023528416A5 JP2023528416A5 (https=) 2024-06-04
JPWO2021247426A5 JPWO2021247426A5 (https=) 2024-06-04
JP7767322B2 true JP7767322B2 (ja) 2025-11-11

Family

ID=76601796

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022574199A Active JP7767322B2 (ja) 2020-06-04 2021-05-28 抗ａｂｃｇ２抗体及びそれらの使用
JP2025182305A Pending JP2026053316A (ja) 2020-06-04 2025-10-29 抗ａｂｃｇ２抗体及びそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182305A Pending JP2026053316A (ja) 2020-06-04 2025-10-29 抗ａｂｃｇ２抗体及びそれらの使用

Country Status (7)

Country Link
US (1) US20230212305A1 (https=)
EP (1) EP4161650A1 (https=)
JP (2) JP7767322B2 (https=)
CN (1) CN116323662A (https=)
AU (1) AU2021284240A1 (https=)
CA (1) CA3182472A1 (https=)
WO (1) WO2021247426A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
WO2025222167A1 (en) * 2024-04-19 2025-10-23 Zb17 Llc Methods of treatment
WO2025222168A1 (en) * 2024-04-19 2025-10-23 Zb17 Llc Methods of treatment
WO2025222170A1 (en) * 2024-04-19 2025-10-23 Zb17 Llc Methods of treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502062A (ja) 2014-11-20 2018-01-25 エンクマフ アーゲー Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体
JP2018504113A (ja) 2015-01-08 2018-02-15 蘇州康寧傑瑞生物科技有限公司 共通軽鎖を有する二重特異性抗体又は抗体混合物
US20190248912A1 (en) 2016-09-14 2019-08-15 Peking Unversity Abcg2 monoclonal antibody and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
TW197439B (https=) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
JPH08500973A (ja) 1992-05-21 1996-02-06 ザ ペン ステイト リサーチ ファウンデーション タキソール、関連タキサン及び他の新規な抗癌／抗ウイルス性化合物原料としてのイチイ培養組織
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
US6063621A (en) * 1992-10-27 2000-05-16 Queen's University At Kingston Antibodies to a multidrug resistance protein
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
WO1998008833A1 (en) 1996-08-26 1998-03-05 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
EP0961619A4 (en) 1996-09-27 2001-09-26 Bristol Myers Squibb Co HYDROLYSABLE DRUGS FOR THE RELEASE OF ANTI-CANCER DRUGS IN METASTATIC CELLS
AU4966597A (en) 1996-11-19 1998-06-10 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
IL133585A0 (en) 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
WO2003035685A1 (en) * 2001-10-24 2003-05-01 Solvo Biotechnology Inc. Use of a half-transporter protein of the abcg-family for selecting cells and in gene therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502062A (ja) 2014-11-20 2018-01-25 エンクマフ アーゲー Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体
JP2018504113A (ja) 2015-01-08 2018-02-15 蘇州康寧傑瑞生物科技有限公司 共通軽鎖を有する二重特異性抗体又は抗体混合物
US20190248912A1 (en) 2016-09-14 2019-08-15 Peking Unversity Abcg2 monoclonal antibody and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Int. J. Cancer，1989年，Vol.44，pp.738-743
Oncotarget，2015年，Vol.6, No.29，pp.27714-27724

Also Published As

Publication number Publication date
AU2021284240A1 (en) 2022-12-08
US20230212305A1 (en) 2023-07-06
JP2023528416A (ja) 2023-07-04
CA3182472A1 (en) 2021-12-09
EP4161650A1 (en) 2023-04-12
CN116323662A (zh) 2023-06-23
JP2026053316A (ja) 2026-03-25
WO2021247426A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
JP7815595B2 (ja) 抗ｍｄｒ１抗体およびその使用
JP7716623B2 (ja) 排出ポンプ－癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
JP7767322B2 (ja) 抗ａｂｃｇ２抗体及びそれらの使用
JP7768902B2 (ja) Ａｂｃｇ２排出ポンプ－がん抗原多重特異性抗体並びにそれらに関連する組成物、試薬、キット、及び方法
EP4244257A1 (en) Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
JP7747741B2 (ja) 抗ａｂｃｃ１抗体及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250903

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251029

R150 Certificate of patent or registration of utility model

Ref document number: 7767322

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150